Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Mohammed Snober, Richard Syzdlo, PhD, Jane Apperley, MB ChB MD, Aristeidis Chaidos, MD PhD, Edward Kanfer, PhD, Dragana Milojkovic, MBBS, PhD, Eduardo Olavarria, MD PhD, Renuka Palanicawandar, MD MRCP, FRCPath, Jiri Pavlu, MD MRCP, FRCPath, Jeannie F Todd, PhD, Nina Salooja, MD

Blood (2018) 132 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2018-99-114229

Published: 2018

Journal Articles

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Denis-Claude Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD, Philippe Lewalle, MD, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva-Maria Wagner, MD, Halvard Bonig, MD, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2018) 132 (Supplement 1): 120.

https://doi.org/10.1182/blood-2018-99-119086

Published: 2018

Journal Articles

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

Andrew James Innes, PhD FRCPath, MRCP, Philippa Woolley, MRCP, MBBS, Richard Szydlo, PhD, Sara Lozano, Fiona Fernando, MBChB, Divya Bansal, Renuka Palanicawandar, MD MRCP,FRCPath, Elisabet Nadal-Melsio, MD, Eva Yebra-Fernandez, MD, Jane Apperley, MB ChB MD, Eduardo Olavarria, MD PhD, Jiri Pavlu, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2018-99-117311

Published: 2018

Journal Articles

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Philippa Woolley, MRCP, MBBS, David Slade, Richard Syzdlo, PhD, George Nasry Nesr, MB BCh, Simone Claudiani, MD, Irene Caballes, RN, Fiona Fernando, MBChB, Jiri Pavlu, MD MRCP, FRCPath, Renuka Palani, MD, Edward Kanfer, FRCP, Eduardo Olavarria, MD PhD, Dragana Milojkovic, MBBS, PhD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 5746.

https://doi.org/10.1182/blood-2018-99-114420

Published: 2018

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Sandra Cohen, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Eduardo Olavarria, MD PhD, Dominik Selleslag, MD, Manfred Rudiger, Jurjen Velthuis, PhD, Karen Reitsma, PhD, Lisya Gerez, Jeroen Rovers, MDPhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2015) 126 (23): 4391.

https://doi.org/10.1182/blood.V126.23.4391.4391

Published: 2015

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Blood (2015) 126 (23): 4403.

https://doi.org/10.1182/blood.V126.23.4403.4403

Published: 2015

Journal Articles

Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

Blood (2015) 126 (23): 1958.

https://doi.org/10.1182/blood.V126.23.1958.1958

Published: 2015

Journal Articles

The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes

Blood (2015) 126 (23): 3223.

https://doi.org/10.1182/blood.V126.23.3223.3223

Published: 2015

Journal Articles

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Franck E. Nicolini, MD PhD, Grzegorz W. Basak, MD PhD, Dong-Wook Kim, MD PhD, Eduardo Olavarria, MD PhD, Javier Pinilla-Ibarz, MD PhD, Jane F. Apperley, MD, Timothy P. Hughes, MD, Dietger Niederwieser, MD, Michael J. Mauro, MD, Charles Chuah, MD PhD, Andreas Hochhaus, MD, Giovanni Martinelli, MD PhD, Maral DerSarkissian, PhD, Andrew Kageleiry, BS, Mo Yang, PhD, Hui Huang, MBA, PhD, Lisa J. McGarry, MPH, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 480.

https://doi.org/10.1182/blood.V126.23.480.480

Published: 2015

Journal Articles

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

Maria-Victoria Mateos, MD PhD, Miguel T Hernandez, MD, Pilar Giraldo, MD PhD, Javier De La Rubia, Felipe de Arriba, Lucía López-Corral, MD PhD, Laura Rosiñol, MD PhD, Bruno Paiva, PhD, Luis Palomera, Joan Bargay, MD, Albert Oriol, MD, Felipe Prosper, MD, Javier López, Eduardo Olavarría, MD, Nuria Quintana, Jose Luis García, Joan Blade, Juan José Lahuerta, MD PhD, Jesus F. San Miguel

Blood (2014) 124 (21): 3465.

https://doi.org/10.1182/blood.V124.21.3465.3465

Published: 2014

Journal Articles

High Mortality Associated with Neurological Complications after Allogeneic Stem Cell Transplantation

Sara Lozano, MD, Amaya Zabalza, Intza Aoiz, Mohamed Hamdi Djatri, Pedro Arregui, MD, Ivan Quispe, MD, Mari Cruz Montoya, Montserrat Alvarellos, Patricia Garcia Ramirez, Ana Gorosquieta, Katy Perez Equiza, Eduardo Olavarria, MD PhD

Blood (2014) 124 (21): 5843.

https://doi.org/10.1182/blood.V124.21.5843.5843

Published: 2014

Journal Articles

Alemtuzumab As Pre-Conditioning Is Safe and Feasible in Patients with T-Cell Lymphoid Neoplasms Undergoing Allogeneic Stem Cell Transplantation

Sara Lozano, MD, Amaya Zabalza, Intza Aoiz, Mohamed Hamdi Djatri, Pedro Arregui, MD, Ivan Quispe, MD, Mari Cruz Montoya, Montserrat Alvarellos, Patricia Garcia Ramirez, Katy Perez Equiza, Ana Gorosquieta, Eduardo Olavarria, MD PhD

Blood (2014) 124 (21): 5863.

https://doi.org/10.1182/blood.V124.21.5863.5863

Published: 2014

Journal Articles

Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT

Blood (2013) 122 (21): 2156.

https://doi.org/10.1182/blood.V122.21.2156.2156

Published: 2013

Journal Articles

Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up

Rafael F. Duarte, MD, PhD, Ariane Boumendil, PhD, Francesco Onida, MD, Ian H Gabriel, Dr, Reyes Arranz, MD, William Arcese, MD, Xavier Poire, MD, Guido Kobbe, MD, Franco Narni, MD, Agostino Cortelezzi, MD, Eduardo Olavarría, MD, Norbert Schmitz, M.D. Ph.D., Anna Sureda, MD, Peter Dreger, MD

Blood (2013) 122 (21): 2094.

https://doi.org/10.1182/blood.V122.21.2094.2094

Published: 2013

Journal Articles

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Blood (2013) 122 (21): 5190.

https://doi.org/10.1182/blood.V122.21.5190.5190

Published: 2013

Journal Articles

Voriconazole for Secondary Prophylaxis of Invasive Fungal Infection in Allogeneic Stem Cell Transplant Recipients: Results of the VOSIFI Study. on Behalf of the VOSIFI Study Group and the Infectious Diseases Working Party of the European Bone and Marrow Transplantation Group.

Catherine Cordonnier, MD, Hermann Einsele, MD, Montserrat Rovira, MD, Johan Maertens, Eduardo Olavarria, MD, Catherine Faucher, MD, Oliver A Cornely, MD, Rafael De La Camara, MD, Claus-Peter Heussel, MD, Marc Pineau, MD, Per T. Ljungman, MD, PhD

Blood (2008) 112 (11): 1159.

https://doi.org/10.1182/blood.V112.11.1159.1159

Published: 2008

Journal Articles

T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies

B. R Patel, Keiren Kirkland, R. Pearce, Richard E Clark, Charles F. Craddock, BM, MRCP, MRCPath, Effie Liakopolou, Adele K Fielding, PhD, Stephen Mackinnon, MD, Eduardo Olavarria, MD, Michael N Potter, Nigel H. Russell, MD, Bronwen E. Shaw, Anthony H. Goldstone, FRCP, FRCPath, David I Marks, MD

Blood (2008) 112 (11): 4413.

https://doi.org/10.1182/blood.V112.11.4413.4413

Published: 2008

Journal Articles

Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies

Ian H Gabriel, Juliet Sharon, Eduardo Olavarria, MD, Amin Rahemtulla, Edward Kanfer, David Marin, Dragana Milojkovic, Katayoun Rezvani, MD, PhD, Donald MacDonald, Richard M. Szydlo

Blood (2008) 112 (11): 2378.

https://doi.org/10.1182/blood.V112.11.2378.2378

Published: 2008

Journal Articles

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Hugues de Lavallade, MD, Dragana Milojkovic, MD, Jamshid S. Khorashad, MD, Alistair Reid, PhD, Eduardo Olavarria, MD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1045.

https://doi.org/10.1182/blood.V110.11.1045.1045

Published: 2007

NARROW

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

High Mortality Associated with Neurological Complications after Allogeneic Stem Cell Transplantation

Alemtuzumab As Pre-Conditioning Is Safe and Feasible in Patients with T-Cell Lymphoid Neoplasms Undergoing Allogeneic Stem Cell Transplantation

Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT

Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Voriconazole for Secondary Prophylaxis of Invasive Fungal Infection in Allogeneic Stem Cell Transplant Recipients: Results of the VOSIFI Study. on Behalf of the VOSIFI Study Group and the Infectious Diseases Working Party of the European Bone and Marrow Transplantation Group.

T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies

Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only